References
Bone histology in incipient and advanced renal failure. Kidney Int 1976;9: 355-62. 15 Ott SM, Maloney NA, Coburn JW, Alfrey AC, Sherrard DJ. The Patients selected to receive vasopressin were infused at a rate of 0-4 U/min for six hours. If bleeding stopped the rate of vasopressin infusion was decreased to 0-2 U/min for the following six hours, then decreased to 0-1 U/min for a further six hours, and finally stopped if no further bleeding occurred. Patients allocated to receive somatostatin received a bolus dose of 250 ,ug followed by a constant infusion of 256 iLg/h for 24 hours. Twelve patients received vasopressin and 10 somatostatin. In 18 of the 22 patients vasopressin or somatostatin was used as a first line treatment. In the four remaining patients the varices had been injected on admission as an initial treatment but, because of continued bleeding, they were randomised to receive one or other drug (one vasopressin and three somatostatin).
Successful control of variceal haemorrhage was defined as the stopping of bleeding as evidenced b-y the absence of fresh blood in the nasogastric aspirate, stable packed cell volume, or absence of other overt signs of continued bleeding during the 18-24 hours of administration of the vasoactive drug. If haemorrhage was not controlled by the vasoactive drug balloon tamponade of the oesophagus was undertaken using either a Minnesota or a Sengstaken Blakemore tube.
Results

SOMATOSTATIN
The variceal haemorrhage was successfully controlled in all 10 patients receiving somatostatin (fig 1) . Seven of these patients were subsequently treated with injection sclerotherapy (one to three days later) without any further episodes of bleeding. The three others, however, rebled before definitive treatment could be undertaken.
One of the patients who rebled had been randomised to receive somatostatin after a massive haematemesis following emergency sclerotherapy. The haemorrhage was successfully controlled by infusion of somatostatin, but he rebled on two further occasions after the infusion of somatostatin had been stopped. In both cases infusion of somatostatin was Somatostatin has been shown to reduce splanchnic blood flow in experimental animals'6 "I and in man." On the basis of 277 these initial studies and the observation that somatostatin lowers wedged hepatic venous pressure in patients with cirrhosis the hormone was suggested to be of possible value in the management of patients presenting with acute variceal haemorrhage."1 Reports on the effects of somatostatin on hepatic haemodynamics in cirrhosis have, however, been contradictory.
Thus an infusion of somatostatin (1 jig/kg body weight/min) has been reported to reduce wedged hepatic venous pressure in man." Similarly,-Bosch et al observed that an injection (1 jtg/kg body weight) or an infusion (7-5 ,ug/min) of somatostatin significantly decreased both wedged hepatic venous pressure and estimated liver blood flow in cirrhotic patients. '7 In contrast, Sonnenberg et al reported that an infusion of somatostatin 250 jig/h had no effect on wedged hepatic venous pressure or liver blood flow in cirrhotic patients."9 The rate of infusion of somatostatin used by Sonnenberg et al (3-0 jxg/kg body weight/h) was lower than that used in other clinical studies and roughly midway between the rates of infusion of the hormone that either have had no effect or have significantly lowered portal pressure in cirrhotic rats." Furthermore, we have previously shown that in cirrhotic rats the beneficial effects of an infusion of somatostatin on hepatic haemodynamics are enhanced by prior bolus administration of the hormone."1 It therefore seems likely that the conflicting reports on the effects of somatostatin on hepatic haemodynamics in cirrhotic patients may be related to the amount given and the mode of administration.
The precise mode of action of somatostatin has not yet been established. The rapidity of onset of its effects on hepatic haemodynamics in experimental animals and in man suggests that the peptide acts directly on the smooth muscle of the splanchnic blood vessels."' Although bleeding stopped during the infusion of somatostatin in all 10 In eight pairs the diabetic was shorter, and in the remainder the cotwins were the same height. In those dbetics who were shorter than their cotwins at diagnosis the average period of growth delay before diagnosis was at least 35 weeks; by contrast, the mean duration of symptoms was only six weeks. No cause for the growth delay other than the diabetes was known in any of the twins. These findings show that the onset of insulin dependent diabetes may be a slow process, with delay occurring several months before symptoms appear.
Introduction
Growth is a sensitive indicator of health in childhood. Uncontrolled diabetes retards growth: before the discovery of insulin growth stopped completely in children who developed diabetes.' We have used these observations to determine whether diabetes can be present, as shown by growth delay, before the appearance of symptoms.
Studies of heights at diagnosis in diabetic children have produced conflicting results. In most the diabetics were found to be taller than expected,2-' although some studies showed that their heights were normal8 10 1 or that they were shorter.12-"4 These discrepancies may be due to the difficulty in obtaining exactly matched control groups. When comparing heights the groups must be accurately matched for social class, racial origin, and parental height. The ideal control for a diabetic child is his unaffected identical twin, as twins usually grow at the same rate and to the same final height.", We studied the heights of identical twins discordant for insulin dependent diabetes at the time of diagnosis of the diabetic twin in order (a) to determine whether the diabetic was taller or shorter at diagnosis than his unaffected cotwin and (b), if there was a difference, to estimate how long before diagnosis growth had been affected.
Subjects and methods
We studied identical twins included in the King's College Hospital survey. Monozygosity was established as described."6
